Trial Profile
A first in human, open label, single center, single ascending dose trial to assess the safety, tolerability and pharmacokinetic parameters of CN128 in healthy volunteers
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Jun 2017
Price :
$35
*
At a glance
- Drugs CN 128 (Primary)
- Indications Iron overload
- Focus Adverse reactions; First in man; Pharmacokinetics
- 08 Jun 2017 New trial record